EWTX
NASD Edgewise Therapeutics, Inc.$38.45 ↑ +0.00 (+0.00%) Trading Up from the previous close of $38.45, $0.91 below the day’s high of $39.36
- YTD change
- +54.95%
- vs 20-day SMA
- -8.05%
- vs 200-day SMA
- +9.14%
Price ranges
Price & Performance
+4.61 (+13.62%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 20.7% away from all-time highs of $48.51
- EWTX is up 55% since the beginning of the year
- EWTX is up 154% over the past 12 months
- EWTX is down 13% over the past 1 month
- 11% of all EWTX investors are betting against EWTX
EWTX reads not so good: price sits above one of the two key moving averages, the 12-month move is +161.4%.
- Previous minute
- +$0.00
- Last hour
- +$0.45
- Last 5 days
- -7.13%
- vs 8-day SMA
- -4.07%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
